| __timestamp | Dr. Reddy's Laboratories Limited | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 38783000000 | 17986000 |
| Thursday, January 1, 2015 | 42585000000 | 32480000 |
| Friday, January 1, 2016 | 45702000000 | 68081000 |
| Sunday, January 1, 2017 | 46372000000 | 169906000 |
| Monday, January 1, 2018 | 46910000000 | 248932000 |
| Tuesday, January 1, 2019 | 48890000000 | 354100000 |
| Wednesday, January 1, 2020 | 50129000000 | 433300000 |
| Friday, January 1, 2021 | 54559000000 | 583300000 |
| Saturday, January 1, 2022 | 62081000000 | 752700000 |
| Sunday, January 1, 2023 | 105931000000 | 887600000 |
| Monday, January 1, 2024 | 77201000000 | 1007200000 |
Unlocking the unknown
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited, from 2014 to 2023.
Dr. Reddy's Laboratories, a global pharmaceutical giant, has consistently reported higher SG&A expenses, peaking in 2023 with a staggering 105% increase from 2014. In contrast, Neurocrine Biosciences, a leader in neuroscience therapies, has shown a steady rise in SG&A expenses, reflecting a 48-fold increase over the same period.
This disparity highlights the contrasting scales and operational strategies of these companies. While Dr. Reddy's focuses on expansive global operations, Neurocrine's growth is driven by targeted innovation in niche markets. Missing data for 2024 suggests ongoing financial adjustments.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Bristol-Myers Squibb Company or Dr. Reddy's Laboratories Limited: Who Manages SG&A Costs Better?
Zoetis Inc. vs Dr. Reddy's Laboratories Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Merus N.V.
Dr. Reddy's Laboratories Limited and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Dr. Reddy's Laboratories Limited or Xencor, Inc.: Who Manages SG&A Costs Better?